Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents Senologie - Zeitschrift für Mammadiagnostik und -therapie 2019; 16(03): 182-184DOI: 10.1055/a-0978-3410 Aktuell diskutiert © Georg Thieme Verlag KG Stuttgart · New York Stellungnahme der DGS zur Bisphosphonattherapie mit Zolendronat oder Clodronat beim Mammakarzinom Recommend Article Abstract Buy Article Full Text References Literatur 1 Becker T, Lipscombe L, Narod S. et al. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc 2012; 60: 1761-1767 2 Coleman RE, Banks LM, Girgis SI. et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8: 119-127 3 Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e. V. Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern (AWMF-Register-Nr.: 183/001). (2017). Im Internet: http://www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2017 . Stand: 18.07.2019 4 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0, 2017 AWMF Registernummer: 032-045OL (2018). http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom . Stand: 18.07.2019 5 Francis PA, Pagani O, Fleming GF. et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018; 379: 122-137 6 Brufsky AM, Harker WG, Beck JT. et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118: 1192-1201 7 Coleman R, de Boer R, Eidtmann H. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405 8 Ben-Aharon I, Vidal L, Rizel S. et al. Bisphosphonates in the adjuvant setting of breast cancer therapy – effect on survival: a systematic review and meta-analysis. PLoS One 2013; 8: e70044 9 Early Breast Cancer Trialistsʼ Collaborative. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353-1361 10 O’Carrigan B, Wong MH, Willson ML. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10: CD003474 11 Gnant M, Mlineritsch B, Stoeger H. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641
